文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性去势抵抗性前列腺癌患者接受一周期[177Lu]Lu-PSMA I&T放射性配体治疗后早期生化与影像学反应

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-07-21

这项回顾性研究纳入40例接受中位3(2-9)周期[177Lu]Lu-PSMA I&T放射性配体治疗的转移性去势抵抗性前列腺癌患者,评估一周期后早期PSMA PET影像学反应及其对总反应和生存的预测作用。结果显示早期PSMA PET影像学反应与总生存无关,而早期PSA进展提示总体进展和不良临床结局。

要点

  • 一周期[177Lu]Lu-PSMA I&T后生化部分缓解8/40(20.0%)、疾病稳定22/40(55.0%)、疾病进展10/40(25%)。
  • 早期PSMA PET影像学反应与总生存无关,不应据此过早终止治疗。
  • 一周期后早期PSA进展提示总体进展和不良临床结局。

核心结论

  • 在这项回顾性队列中,早期PSMA PET影像学反应与总生存无关,因此不应过早终止治疗。
  • 相反,一周期[177Lu]Lu-PSMA I&T放射性配体治疗后早期PSA进展是总体进展和不良临床结局的指标。

研究设计与样本

  • 回顾性研究纳入40例转移性去势抵抗性前列腺癌患者,接受中位3(2-9)周期[177Lu]Lu-PSMA I&T放射性配体治疗。
  • 生化反应依据PCWG3标准按血清PSA相对变化判定,影像学反应指PSMA衍生总存活肿瘤体积(以总病灶PSMA即TLP表示)的相对变化。

主要发现

  • 一周期放射性配体治疗后,生化部分缓解8/40(20.0%)、疾病稳定22/40(55.0%)、疾病进展10/40(25%)。
  • PSMA PET上早期分子部分缓解12例(30.0%)、疾病稳定19例(47.5%)、疾病进展9例(22.5%)。
  • PSA最低值中位在1(1-5)周期达到,TLP最低值中位在2(1-6)周期达到。
  • 总体生化部分缓解19例(47.5%)、疾病稳定11例(27.5%)、疾病进展10例(25%);PSMA PET上分子完全缓解4例、部分缓解24例(60.0%)、疾病稳定4例(10.0%)、疾病进展8例(20.0%)。
  • 早期生化或影像学反应与较长总生存无关;总体生化缓解者中位总生存22.7个月 vs 非缓解者14.4个月(p=0.08);早期PSA进展者中位总生存12.2个月 vs 生化疾病稳定/部分缓解者18.7个月(p=0.09)。

临床怎么用

  • 原文结论指出早期PSMA PET影像学反应与总生存无关,因此不应过早终止治疗。
  • 原文结论指出一周期[177Lu]Lu-PSMA I&T后早期PSA进展是总体进展和不良临床结局的指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to investigate very early radiographic PSMA PET response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) and to assess its role in predicting overall response and survival. METHODS: This retrospective study enrolled 40 mCRPC patients who were treated with a median of 3 (2-9) [177Lu]Lu-PSMA I&T RLT cycles. Biochemical response was based on the relative change of serum PSA according to PCWG3 criteria, while radiographic response referred to the relative change of PSMA-derived total viable tumor volumes expressed as total lesion PSMA (TLP). RESULTS: After one cycle of RLT, biochemical partial response (PR) was seen in 8/40 (20.0%), stable disease (SD) in 22/40 (55.0%), and progressive disease (PD) in 10/40 (25%) patients. In PSMA PET, very early molecular PR was observed in 12 (30.0%), SD in 19 (47.5%), and PD in 9 (22.5%) subjects. The PSA and TLP nadir were achieved after a median of 1 (1-5) and 2 (1-6) cycles, respectively. Nineteen (47.5%) patients showed overall biochemical PR, 11 (27.5%) had SD, and 10 (25%) experienced PD. In PSMA-directed PET, 4 patients experienced molecular complete response (CR), 24 (60.0%) had PR, 4 (10.0%) SD, and 8 (20.0%) PD. Early biochemical or radiographic response was not associated with longer overall survival (OS). Overall biochemical responders had a nearly significantly longer median OS (22.7 months) than non-responders (14.4 months, p = 0.08). Early PSA progression was associated with shorter OS (12.2 months), compared to biochemical SD/PR (18.7 months, p = 0.09). CONCLUSION: In this retrospective cohort, there was no association between early PSMA PET radiographic response and overall survival; hence, treatment should not be prematurely discontinued. In contrast, early PSA progression after one cycle of [177Lu]Lu-PSMA I&T RLT was an indicator of overall progression and poor clinical outcome.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cytawa W, Hendel R, Tomasik B, et al. Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2023. PMID: 37474735. doi:10.1007/s00259-023-06326-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。